Trial Search Results

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: GE Healthcare

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Cardiac Perfusion Rest/Stress Digital PET/CT
  • Drug: N-13 ammonia
  • Drug: Regadenoson

Eligibility


Inclusion Criteria:

   - Patient is ≥ 18 years old at the time of the scan

   - Patient has known or suspected coronary artery disease

   - Patient has had a recent or will be scheduled for a diagnostic coronary angiogram

   - Patient provides written informed consent

   - Patient is referred for myocardial perfusion scan

   - Patient is capable of complying with study procedures

   - Patient is able to remain still for duration of imaging procedure (approximately 60
   minutes total for both PET/CT)

Exclusion Criteria:

   - Patients who are pregnant or breast feeding

   - Patients with contraindications to regadenoson

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jordan Ciscernos
650-725-6409
Recruiting